The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.